Simon E Aspland from 801 Bond St, Baltimore, MD 21231, age 53, Phone: 4102760497

Resumes

Vp Intellectual Property And Licensing At Acidophil Llc

view source

Position:

VP Intellectual Property and Operations at ZuvaChem Inc., VP Intellectual Property and Operations at Acidophil LLC

Location:

Baltimore, Maryland Area

Industry:

Biotechnology

Work:

ZuvaChem Inc. since 2009
VP Intellectual Property and Operations
Acidophil LLC since Jul 2005
VP Intellectual Property and Operations
Arginetix Jan 2008 - Sep 2009
Co-Founder & Director of Research and Development
Dihedron Mar 2003 - Jul 2005
Senior Scientist
Stell Jun 2001 - Dec 2003
Co-founder and senior scientist

Education:

University of Cambridge 1992 - 1998
PhD, Molecular biology University of Southampton 1989 - 1993
BSc, Molecular and Cellular Biology

Simon Aspland

view source

Us Patents

Genetically Modified Cows Having Reduced Susceptibility To Mad Cow Disease
view source
US Patent:

20030051264, Mar 13, 2003
Filed:

Jul 29, 2002
Appl. No.:

10/209194
Inventors:

Monika Liljedahl - La Jolla CA, US
Simon Aspland - San Diego CA, US
International Classification:

A01K067/027
C12N005/06
US Classification:

800/015000, 435/325000
Abstract:

The present invention relates to cow cells in which a gene associated with mad cow disease has been modified to reduce susceptibility to mad cow disease, cows having reduced susceptibility to mad cow disease, nucleic acids for making such cells and cows, and products obtained from such cows. The invention also includes methods of making each of the foregoing.

Tissues Or Organs For Use In Xenotransplantation
view source
US Patent:

20030092174, May 15, 2003
Filed:

May 14, 2002
Appl. No.:

10/147286
Inventors:

Monika Liljedahl - La Jolla CA, US
Daniela Marcantonio - San Diego CA, US
Simon Aspland - San Diego CA, US
International Classification:

C12N005/02
A61K031/711
C07H021/04
US Classification:

435/325000, 536/023100, 514/044000
Abstract:

The present invention provides cells, tissues or organs for use in cell therapy or xenotransplantation in which at least one gene comprising an antigenic determinant recognized by a recipient organism has been disrupted. The present invention also includes methods of administering such cells and transplanting such tissues or organs in which genes encoding antigenic determinants recognized by the recipient organism have been disrupted.

Tissues Or Organs For Use In Xenotransplantation
view source
US Patent:

20030153044, Aug 14, 2003
Filed:

Nov 21, 2002
Appl. No.:

10/303686
Inventors:

Monika Liljedahl - La Jolla CA, US
Daniela Marcantonio - San Diego CA, US
Simon Aspland - San Diego CA, US
International Classification:

C12P021/02
C12N005/06
C07H021/04
C08B037/00
C12N009/10
C12N015/85
US Classification:

435/069100, 435/193000, 435/320100, 435/325000, 435/349000, 435/455000, 536/023200, 536/053000
Abstract:

The present invention provides cells, tissues or organs for use in cell therapy or xenotransplantation in which at least one gene comprising an antigenic determinant recognized by a recipient organism has been disrupted. The present invention also includes methods of administering such cells and transplanting such tissues or organs in which genes encoding antigenic determinants recognized by the recipient organism have been disrupted.

Methods And Compositions For Using Zinc Finger Endonucleases To Enhance Homologous Recombination
view source
US Patent:

20030232410, Dec 18, 2003
Filed:

Mar 20, 2003
Appl. No.:

10/395816
Inventors:

Monika Liljedahl - La Jolla CA, US
Simon Aspland - San Diego CA, US
David Segal - Tucson AZ, US
International Classification:

C12P021/02
C12N015/85
C12N005/06
US Classification:

435/069100, 435/455000, 435/325000
Abstract:

Embodiments relate to methods of generating a genetically modified cell. The methods can include providing a primary cell containing an endogenous chromosomal target DNA sequence in which it is desired to have homologous recombination occur. The methods also can include providing a zinc finger endonuclease (ZFE) that includes an endonuclease domain that cuts DNA, and a zinc finger domain that includes a plurality of zinc fingers that bind to a specific nucleotide sequence within the endogenous chromosomal target DNA in the primary cell. Further, the methods can include contacting the endogenous chromosomal target DNA sequence with the zinc finger endonuclease in the primary cell such that the zinc finger endonuclease cuts both strands of a nucleotide sequence within the endogenous chromosomal target DNA sequence in the primary cell, thereby enhancing the frequency of homologous recombination in the endogenous chromosomal target DNA sequence. The methods also include providing a nucleic acid comprising a sequence homologous to at least a portion of said endogenous chromosomal target DNA such that homologous recombination occurs between the endogenous chromosomal target DNA sequence and the nucleic acid.

Small Molecule Compositions And Methods For Increasing Drug Efficiency Using Compositions Thereof
view source
US Patent:

20050148534, Jul 7, 2005
Filed:

Sep 22, 2004
Appl. No.:

10/948364
Inventors:

Angelo Castellino - San Diego CA, US
Carlo Ballatore - San Diego CA, US
Simon Aspland - San Diego CA, US
Joel Desharnais - San Diego CA, US
Michael Newman - San Diego CA, US
Chengzao Sun - San Diego CA, US
Peter Wirsching - San Diego CA, US
International Classification:

A61K048/00
A61K031/7076
A61K031/7072
A61K031/522
A61K031/513
US Classification:

514044000, 514045000, 514049000, 514263240, 514269000, 514063000, 514151000, 514081000, 514084000, 536027100, 536028100, 544243000, 544244000, 544269000, 544309000
Abstract:

In certain embodiments, provided herein are compositions and methods for increasing drug efficiency. The conjugates provided are in certain embodiments, for compositions and methods in treatment of variety of diseases and have the formula 1: D-L-S (1) or formula 2: D-L-S′ (2) wherein D is a drug moiety; L, which may or may not be present, is a non-releasing linker moiety; S is a substrate for a kinase, other than a hexokinase, a protein kinase or a lipid kinase; and S′ is a substrate for a phosphotransferase, other than a hexokinase, a protein kinase or a lipid kinase.

Methods And Compositions For Using Zinc Finger Endonucleases To Enhance Homologous Recombination
view source
US Patent:

20080209587, Aug 28, 2008
Filed:

Oct 17, 2007
Appl. No.:

11/975017
Inventors:

Monika Liljedahl - La Jolla CA, US
Simon Eric Aspland - San Diego CA, US
David J. Segal - Tucson AZ, US
International Classification:

C12N 15/82
A01H 5/00
US Classification:

800278, 800298
Abstract:

Embodiments relate to methods of generating a genetically modified cell. The methods can include providing a primary cell containing an endogenous chromosomal target DNA sequence in which it is desired to have homologous recombination occur. The methods also can include providing a zinc finger endonuclease (ZFE) that includes an endonuclease domain that cuts DNA, and a zinc finger domain that includes a plurality of zinc fingers that bind to a specific nucleotide sequence within the endogenous chromosomal target DNA in the primary cell. Further, the methods can include contacting the endogenous chromosomal target DNA sequence with the zinc finger endonuclease in the primary cell such that the zinc finger endonuclease cuts both strands of a nucleotide sequence within the endogenous chromosomal target DNA sequence in the primary cell, thereby enhancing the frequency of homologous recombination in the endogenous chromosomal target DNA sequence. The methods also include providing a nucleic acid comprising a sequence homologous to at least a portion of said endogenous chromosomal target DNA such that homologous recombination occurs between the endogenous chromosomal target DNA sequence and the nucleic acid.

Methods And Compositions For Using Zinc Finger Endonucleases To Enhance Homologous Recombination
view source
US Patent:

20090305402, Dec 10, 2009
Filed:

Jun 11, 2009
Appl. No.:

12/456111
Inventors:

Monika Liljedahl - La Jolla CA, US
Simon Eric Aspland - San Diego CA, US
David J. Segal - Tucson AZ, US
International Classification:

C12N 5/10
C12N 5/04
C12N 5/06
C12N 5/08
US Classification:

435349, 435419, 435325, 435366, 435363, 435353, 435354
Abstract:

Described herein are methods of generating a genetically modified cell by providing a zinc finger endonuclease (ZFE) that includes an endonuclease domain that cuts DNA, and a zinc finger domain that includes a plurality of zinc fingers that bind to a specific nucleotide sequence within the endogenous chromosomal target DNA in the primary cell. Further, the methods can include contacting the endogenous chromosomal target DNA sequence with the zinc finger endonuclease in the primary cell such that the zinc finger endonuclease cuts both strands of a nucleotide sequence within the endogenous chromosomal target DNA sequence in the primary cell, thereby enhancing the frequency of homologous recombination in the endogenous chromosomal target DNA sequence.

C-10 Carbamates Of Taxanes
view source
US Patent:

20090306014, Dec 10, 2009
Filed:

Dec 27, 2006
Appl. No.:

12/158174
Inventors:

Carlo Ballatore - Philadelphia PA, US
Angelo J. Castellino - San Diego CA, US
Joel Desharnais - San Diego CA, US
Chengzao Sun - San Marcos CA, US
Simon E. Aspland - Baltimore MD, US
Assignee:

Acidophil llc - Lutherville MD
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:

A61K 31/695
C07F 7/10
A61P 35/00
US Classification:

514 63, 548110
Abstract:

Provided herein are C-10 taxane carbamates and pharmaceutically acceptable derivatives thereof. In certain embodiments, provided herein are compounds, compositions and methods for treating cancer and taupathy.